Literature DB >> 19958166

New emerging potentials for human Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity.

Rita Anzalone1, Melania Lo Iacono, Simona Corrao, Francesca Magno, Tiziana Loria, Francesco Cappello, Giovanni Zummo, Felicia Farina, Giampiero La Rocca.   

Abstract

In recent years, human mesenchymal stem cells (MSC) have been extensively studied. Their key characteristics of long-term self-renewal and a capacity to differentiate into diverse mature tissues favor their use in regenerative medicine applications. Stem cells can be found in embryonic and extraembryonic tissues as well as in adult organs. Several reports indicate that cells of Wharton's jelly (WJ), the main component of umbilical cord extracellular matrix, are multipotent stem cells, expressing markers of bone marrow mesenchymal stem cells (BM-MSC), and giving rise to different cellular types of both connective and nervous tissues. Wharton's jelly mesenchymal stem cells (WJ-MSC) express markers previously characterized in embryonic stem cells (ESC), such as Nanog and Oct3/4A. WJ-MSC further emerge as promising hypoimmunogenic cells, due to the expression of molecules able to modulate NK cells and expand regulatory T-cell populations. Moreover, it is now accepted that the differentiative capacities of such cells span all the mesoderm-derived tissues, extending to neuroectodermal as well as endodermal lineages. In this review, we compare very recent data on the potential of WJ-MSC to undergo hepatocyte-like differentiation with the results obtained from other adult MSC populations. Data in the literature strongly suggest that WJ-MSC can differentiate into diverse cell types, showing a unique ability to cross lineage borders. This, together with their in vitro proliferative potential and their immunoregulatory features, renders these cells extremely promising for regenerative medicine applications in different pathological settings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19958166     DOI: 10.1089/scd.2009.0299

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  82 in total

Review 1.  Umbilical cord-derived mesenchymal stem cells: strategies, challenges, and potential for cutaneous regeneration.

Authors:  Siming Yang; Sha Huang; Changjiang Feng; Xiaobing Fu
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

Review 2.  Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues.

Authors:  Hassan Abdulrazzak; Dafni Moschidou; Gemma Jones; Pascale V Guillot
Journal:  J R Soc Interface       Date:  2010-08-25       Impact factor: 4.118

Review 3.  Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.

Authors:  Rita Anzalone; Melania Lo Iacono; Tiziana Loria; Antonino Di Stefano; Pantaleo Giannuzzi; Felicia Farina; Giampiero La Rocca
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

Review 4.  Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells.

Authors:  Limin Wang; Lindsey Ott; Kiran Seshareddy; Mark L Weiss; Michael S Detamore
Journal:  Regen Med       Date:  2011-01       Impact factor: 3.806

Review 5.  Mesenchymal stem cells as delivery vectors for anti-tumor therapy.

Authors:  Zhenzhen Li; Dongmei Fan; Dongsheng Xiong
Journal:  Stem Cell Investig       Date:  2015-03-26

6.  Size-sieved subpopulations of mesenchymal stem cells from intervascular and perivascular equine umbilical cord matrix.

Authors:  B Corradetti; A Lange-Consiglio; M Barucca; F Cremonesi; D Bizzaro
Journal:  Cell Prolif       Date:  2011-06-06       Impact factor: 6.831

Review 7.  The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine.

Authors:  N Forraz; C P McGuckin
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

Review 8.  Wharton's Jelly Mesenchymal Stromal Cells as a Feeder Layer for the Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells: a Review.

Authors:  Melania Lo Iacono; Rita Anzalone; Giampiero La Rocca; Elena Baiamonte; Aurelio Maggio; Santina Acuto
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

9.  Effect of human Wharton's jelly mesenchymal stem cell paracrine signaling on keloid fibroblasts.

Authors:  Anna I Arno; Saeid Amini-Nik; Patrick H Blit; Mohammed Al-Shehab; Cassandra Belo; Elaine Herer; Marc G Jeschke
Journal:  Stem Cells Transl Med       Date:  2014-01-16       Impact factor: 6.940

10.  Endothelial progenitor cells derived from Wharton's jelly of the umbilical cord reduces ischemia-induced hind limb injury in diabetic mice by inducing HIF-1α/IL-8 expression.

Authors:  Wen-Ching Shen; Chan-Jung Liang; Vin-Cent Wu; Shu-Huei Wang; Guang-Huar Young; I-Rue Lai; Chung-Liang Chien; Seu-Mei Wang; Kwan-Dun Wu; Yuh-Lien Chen
Journal:  Stem Cells Dev       Date:  2013-02-15       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.